Matsui Ryota, Ohashi Manabu, Ri Motonari, Makuuchi Rie, Irino Tomoyuki, Hayami Masaru, Sano Takeshi, Nunobe Souya
Department of Gastroenterological Surgery, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Department of Gastroenterological Surgery, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Eur J Surg Oncol. 2025 Mar 12;51(7):109762. doi: 10.1016/j.ejso.2025.109762.
The impact of preoperative anemia on long-term survival outcomes after gastrectomy remains unclear. This study determined the effect of preoperative anemia on long-term survival outcomes in patients undergoing gastrectomy for gastric cancer.
This retrospective cohort study included consecutive patients who underwent radical gastrectomy for primary pStages I-III gastric cancer between May 2006 and March 2017. According to the World Health Organization hemoglobin classification, ≥13.0 g/dL for men and ≥12.0 g/dL for women are considered normal, 11.0-12.9 g/dL for men and 11.0-11.9 g/dL for women as mild anemia, 8.0-10.9 g/dL moderate anemia, and <8.0 g/dL as severe anemia. The primary outcome was overall survival (OS). Comparisons were made using the log-rank test, and prognostic factors were identified using Cox proportional hazards regression analysis.
The median follow-up duration was 60 months. Of 4730 patients, 3066 (64.8 %) were classified as normal, 1093 (23.1 %) as mild, 540 (11.4 %) as moderate, and 31 (0.7 %) as severe anemia. Patients with anemia had poorer survival outcomes than those without anemia (P < 0.001). No differences were found among survival outcomes in OS based on severity. When stratified by pStage, patients with anemia had a poorer survival outcome than those without anemia in each pStage. Multivariate analysis showed that preoperative anemia was an independent poor prognostic factor for OS regardless of blood transfusion (hazard ratios: 1.650, 95 % confidence interval: 1.432-1.902, P < 0.001).
Preoperative anemia, independent of perioperative blood transfusions, may worsen OS in patients with gastric cancer after curative gastrectomy.
术前贫血对胃癌根治术后长期生存结局的影响尚不清楚。本研究确定了术前贫血对接受胃癌根治术患者长期生存结局的影响。
这项回顾性队列研究纳入了2006年5月至2017年3月期间因I-III期原发性胃癌接受根治性胃切除术的连续患者。根据世界卫生组织血红蛋白分类标准,男性血红蛋白≥13.0 g/dL、女性血红蛋白≥12.0 g/dL被视为正常,男性血红蛋白11.0-12.9 g/dL、女性血红蛋白11.0-11.9 g/dL为轻度贫血,8.0-10.9 g/dL为中度贫血,<8.0 g/dL为重度贫血。主要结局为总生存期(OS)。采用对数秩检验进行比较,并使用Cox比例风险回归分析确定预后因素。
中位随访时间为60个月。4730例患者中,3066例(64.8%)血红蛋白正常,1093例(23.1%)为轻度贫血,540例(11.4%)为中度贫血,31例(0.7%)为重度贫血。贫血患者的生存结局比无贫血患者差(P<0.001)。根据贫血严重程度在总生存期的生存结局方面未发现差异。按p分期分层时,各p分期中贫血患者的生存结局均比无贫血患者差。多因素分析显示,无论是否输血,术前贫血都是总生存期的独立不良预后因素(风险比:1.650,95%置信区间:1.432-1.902,P<0.001)。
术前贫血,独立于围手术期输血,可能会使胃癌根治术后患者的总生存期恶化。